BDSXNasdaqServices-Medical LaboratoriesFiscal year ends December 31
BIODESIX INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$23.40−0.26 (-1.10%)
Close on Oct 19, 2026
- Market cap
- $240.93M
- P/E (TTM)
- –
- Dividend yield
- –
BIODESIX INC revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Diagnostic Tests | $79.20M | $64.71M | $45.19M | $34.54M | $48.94M | $40.92M | $17.32M | 89.5% | +22.4% |
| Development Services | $9.30M | $6.62M | $3.90M | – | – | – | – | 10.5% | +40.6% |
| Services and Other | – | – | – | $3.67M | $5.57M | $4.64M | $7.24M | – | – |
| Lung Diagnostic Revenue | – | – | – | – | – | $12.60M | – | – | – |
| COVID-19 Test Revenue | – | – | – | – | – | $28.30M | – | – | – |
| Biopharma Services and Other | – | – | $3.90M | $3.67M | – | – | – | – | – |
| Lung Diagnostic Testing | – | $64.71M | $45.19M | – | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Biodesix's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.